Carnitine and chromium co-supplementation affects mental health, hormonal, inflammatory, genetic, and oxidative stress parameters in women with polycystic ovary syndrome

Objective: The aim of this study was to evaluate the effect of the co-administration of carnitine and chromium on mental health, hormonal, inflammatory and genetic parameters in women with PCOS. Methods: This randomized, double-blinded, placebo-controlled clinical trial was conducted on 54 subjects, aged 18–40 years old. Subjects were randomly allocated to take either 1000 mg/d carnitine plus 200 µg/d chromium as chromium picolinate (n = 26) or placebo (n = 27) for 12 weeks. Results: Carnitine and chromium co-supplementation, compared with the placebo, significantly improved beck depression inventory (β − 0.84; 95% CI, −1.51, −0.17; p = 0.01), general health questionnaire scores (β − 1.13; 95% CI, −2.13, −0.14; p = 0.02) and depression anxiety and stress scale scores (β − 0.96; 95% CI, −0.78, −0.14; p = 0.02). Participants who received carnitine plus chromium supplements had significantly lower total testosterone (β − 0.15 ng/mL; 95% CI, −0.24, −0.06; p = 0.002), hirsutism (β − 0.48; 95% CI, −0.91, −0.06; p = 0.02), high-sensitivity C-reactive protein (hs-CRP) (β − 1.02 mg/L; 95% CI, −1.79, −0.25; p = 0.01), and malondialdehyde (MDA) levels (β − 0.38 µmol/L; 95% CI, −0.56, −0.20; p